EMPLOYMENT AGREEMENTEmployment Agreement • August 9th, 2016 • Impax Laboratories Inc • Pharmaceutical preparations • Delaware
WHEREAS, effective as of August 1, 2016 (the “Effective Date”), the Company desires to employ the Executive, and the Executive desires to be employed by the Company, upon the terms and subject to the conditions set forth in this Agreement; and
ASSET PURCHASE AGREEMENT BETWEEN TEVA PHARMACEUTICAL INDUSTRIES LTD. AND IMPAX LABORATORIES, INC. DATED AS OF JUNE 20, 2016Asset Purchase Agreement • August 9th, 2016 • Impax Laboratories Inc • Pharmaceutical preparations • New York
THIS ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of June 20, 2016 (the “Effective Date”), is made by and between Impax Laboratories, Inc., a Delaware corporation (“Buyer”), and Teva Pharmaceutical Industries Ltd., an Israeli corporation, acting directly or through its Affiliates (“Seller”).
ASSET PURCHASE AGREEMENT AMONG ACTAVIS ELIZABETH LLC ACTAVIS GROUP PTC EHF ACTAVIS HOLDCO US, INC. ACTAVIS LLC ACTAVIS MID ATLANTIC LLC ACTAVIS PHARMA, INC. ACTAVIS SOUTH ATLANTIC LLC ANDRX LLC BREATH LTD. THE RUGBY GROUP, INC. WATSON LABORATORIES,...Asset Purchase Agreement • August 9th, 2016 • Impax Laboratories Inc • Pharmaceutical preparations • New York
THIS ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of June 20, 2016 (the “Effective Date”), is made by and among Impax Laboratories, Inc., a Delaware corporation (“Buyer”), Actavis Elizabeth LLC, a Delaware limited liability company (“Actavis Elizabeth”), Actavis Group PTC Ehf., an Iceland einkahlutafelag (“Actavis PTC”), Actavis Holdco US, Inc., a Delaware corporation (“Actavis Holdco”), Actavis LLC, a Delaware limited liability company (“Actavis LLC”), Actavis Mid Atlantic LLC, a Delaware limited liability company (“Actavis Mid Atlantic”), Actavis Pharma, Inc., a Delaware corporation (“Actavis Pharma”), Actavis South Atlantic LLC, a Delaware liability company (“Actavis South Atlantic”), Andrx LLC, a Delaware limited liability company (“Andrx”), Breath Ltd., a United Kingdom private limited company (“Breath”), The Rugby Group, Inc., a New York corporation (“Rugby”), and Watson Laboratories, Inc., a Nevada corporation (“Watson” and, together with Actavis Elizabeth, Actavis PTC,
SUPPLY AGREEMENT BETWEEN TEVA PHARMACEUTICAL INDUSTRIES LTD. AND IMPAX LABORATORIES, INC. DATED AS OF JUNE 20, 2016Supply Agreement • August 9th, 2016 • Impax Laboratories Inc • Pharmaceutical preparations • New York
This Supply Agreement (this “Supply Agreement”), dated as of June 20, 2016, by and between Impax Laboratories, Inc., a Delaware corporation (“Buyer”), and Teva Pharmaceutical Industries Ltd., an Israeli corporation, acting directly or through its Affiliates (“Teva” or the “Manufacturer”).
SUPPLY AGREEMENT AMONG ACTAVIS ELIZABETH LLC ACTAVIS GROUP PTC EHF ACTAVIS HOLDCO US, INC. ACTAVIS LLC ACTAVIS MID ATLANTIC LLC ACTAVIS PHARMA, INC. ACTAVIS SOUTH ATLANTIC LLC ANDRX LLC BREATH LTD. THE RUGBY GROUP, INC. WATSON LABORATORIES, INC. AND...Supply Agreement • August 9th, 2016 • Impax Laboratories Inc • Pharmaceutical preparations • New York
This Supply Agreement (this “Supply Agreement”), dated as of June 20, 2016, by and among Impax Laboratories, Inc., a Delaware corporation (“Buyer”), Actavis Elizabeth LLC, a Delaware limited liability company (“Actavis Elizabeth”), Actavis Group PTC Ehf., an Iceland einkahlutafelag (“Actavis PTC”), Actavis Holdco US, Inc., a Delaware corporation (“Actavis Holdco”), Actavis LLC, a Delaware limited liability company (“Actavis LLC”), Actavis Mid Atlantic LLC, a Delaware limited liability company (“Actavis Mid Atlantic”), Actavis Pharma, Inc., a Delaware corporation (“Actavis Pharma”), Actavis South Atlantic LLC, a Delaware limited liability company (“Actavis South Atlantic”), Andrx LLC, a Delaware limited liability company (“Andrx”), Breath Ltd., a United Kingdom private limited company (“Breath”), The Rugby Group, Inc., a New York corporation (“Rugby”), and Watson Laboratories, Inc., a Nevada corporation (“Watson” and, together with Actavis Elizabeth, Actavis PTC, Actavis Holdco, Actavis
RESTATEMENT AGREEMENT TO CREDIT AGREEMENTCredit Agreement • August 9th, 2016 • Impax Laboratories Inc • Pharmaceutical preparations • New York
This AMENDED AND RESTATED CREDIT AGREEMENT entered into as of August 4, 2015, as amended and restated as of August 3, 2016, among IMPAX LABORATORIES, INC., a Delaware corporation (the “Borrower” or “Impax”), Royal Bank of Canada, as administrative agent (in such capacity, including any successor thereto, the “Administrative Agent”) and as collateral agent (in such capacity, including any successor thereto, the “Collateral Agent”) under the Loan Documents, the other agents listed on the cover page, and each lender from time to time party hereto (collectively, the “Lenders” and, individually, a “Lender”).
AMENDMENT NO. 1 TO THEAsset Purchase Agreement • August 9th, 2016 • Impax Laboratories Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO THE ASSET PURCHASE AGREEMENT (this “Amendment”) is dated as of June 30, 2016, by and among Impax Laboratories, Inc., a Delaware corporation (“Buyer”), Actavis Elizabeth LLC, a Delaware limited liability company (“Actavis Elizabeth”), Actavis Group PTC Ehf., an Iceland einkahlutafelag (“Actavis PTC”), Actavis Holdco US, Inc., a Delaware corporation (“Actavis Holdco”), Actavis LLC, a Delaware limited liability company (“Actavis LLC”), Actavis Mid Atlantic LLC, a Delaware limited liability company (“Actavis Mid Atlantic”), Actavis Pharma, Inc., a Delaware corporation (“Actavis Pharma”), Actavis South Atlantic LLC, a Delaware limited liability company (“Actavis South Atlantic”), Andrx LLC, a Delaware limited liability company (“Andrx”), Breath Ltd., a United Kingdom private limited company (“Breath”), The Rugby Group, Inc., a New York corporation (“Rugby”), and Watson Laboratories, Inc., a Nevada corporation (“Watson” and, together with Actavis Elizabeth, Actavis PT
FIRST AMENDMENT TO DISTRIBUTION, LICENSE, DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • August 9th, 2016 • Impax Laboratories Inc • Pharmaceutical preparations
This First Amendment to Distribution, License, Development and Supply Agreement (the “Amendment”) is made and entered into effective as of May 31, 2016 (the “Effective Date”) by and between AstraZeneca UK Limited, a company incorporated in England under no. 3674842 whose registered office is at 2 Kingdom Street, London, W2 6BD, England (“AstraZeneca”), and Impax Laboratories, Inc., a Delaware corporation located at 30831 Huntwood Avenue, Hayward, CA 94544 (“Impax”), and amends that certain Distribution, License, Development and Supply Agreement by and between AstraZeneca and Impax dated January 31, 2012 (the “Agreement”). AstraZeneca and Impax are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 1 TO THESupply Agreement • August 9th, 2016 • Impax Laboratories Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO THE SUPPLY AGREEMENT (this “Amendment”) is dated as of June 30, 2016, by and between Impax Laboratories, Inc., a Delaware corporation (“Buyer”) and Teva Pharmaceutical Industries Ltd., an Israeli corporation, acting directly or through its Affiliates (“Manufacturer”).
AMENDMENT NO. 1 TO THESupply Agreement • August 9th, 2016 • Impax Laboratories Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO THE SUPPLY AGREEMENT (this “Amendment”) is dated as of June 30, 2016, by and among Impax Laboratories, Inc., a Delaware corporation (“Buyer”), Actavis Elizabeth LLC, a Delaware limited liability company (“Actavis Elizabeth”), Actavis Group PTC Ehf., an Iceland einkahlutafelag (“Actavis PTC”), Actavis Holdco US, Inc., a Delaware corporation (“Actavis Holdco”), Actavis LLC, a Delaware limited liability company (“Actavis LLC”), Actavis Mid Atlantic LLC, a Delaware limited liability company (“Actavis Mid Atlantic”), Actavis Pharma, Inc., a Delaware corporation (“Actavis Pharma”), Actavis South Atlantic LLC, a Delaware limited liability company (“Actavis South Atlantic”), Andrx LLC, a Delaware limited liability company (“Andrx”), Breath Ltd., a United Kingdom private limited company (“Breath”), The Rugby Group, Inc., a New York corporation (“Rugby”), and Watson Laboratories, Inc., a Nevada corporation (“Watson” and, together with Actavis Elizabeth, Actavis PTC, Actav
AMENDMENT NO. 1 TO THEAsset Purchase Agreement • August 9th, 2016 • Impax Laboratories Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO THE ASSET PURCHASE AGREEMENT (this “Amendment”) is dated as of June 30, 2016, by and between Impax Laboratories, Inc., a Delaware corporation (“Buyer”) and Teva Pharmaceutical Industries Ltd., an Israeli corporation, acting directly or through its Affiliates (“Seller”).
